Patents by Inventor Stacey Ellen Wallace
Stacey Ellen Wallace has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10613094Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: GrantFiled: October 20, 2014Date of Patent: April 7, 2020Assignee: EPITOMICS, INC.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace, Guo-Liang Yu
-
Publication number: 20190382847Abstract: Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B).Type: ApplicationFiled: May 14, 2019Publication date: December 19, 2019Applicant: CepheidInventors: Leena McCann, Stacey Ellen Wallace, Edwin Wei-Lung Lai, Russell Higuchi
-
Publication number: 20190360050Abstract: Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting a set of markers consisting of CRH, IGF2, KRT20, and ANXA10.Type: ApplicationFiled: February 11, 2019Publication date: November 28, 2019Inventors: Russell Higuchi, Stacey Ellen Wallace, Edwin Wei-Lung Lai
-
Patent number: 10329622Abstract: Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B).Type: GrantFiled: March 6, 2014Date of Patent: June 25, 2019Assignee: CepheidInventors: Leena McCann, Stacey Ellen Wallace, Edwin Wei-Lung Lai, Russell Higuchi
-
Patent number: 10202653Abstract: Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting a set of markers consisting of CRH, IGF2, KRT20, and ANXA10.Type: GrantFiled: April 19, 2013Date of Patent: February 12, 2019Assignee: CepheidInventors: Russell Higuchi, Stacey Ellen Wallace, Edwin Wei-Lung Lai
-
Publication number: 20150133325Abstract: Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting a set of markers consisting of CRH, IGF2, KRT20, and ANXA10.Type: ApplicationFiled: April 19, 2013Publication date: May 14, 2015Inventors: Russell Higuchi, Stacey Ellen Wallace, Edwin Wei-Lung Lai
-
Publication number: 20150038370Abstract: The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody. The amino acid at the substitutable position may be substituted for a different amino acid without significantly affecting the activity of the antibody. The subject methods may be employed to change the amino acid sequence of a CDR without significantly reducing the affinity of the antibody of the antibody, in humanization methods, or in other antibody engineering methods. The invention finds use in a variety of therapeutic, diagnostic and research applications.Type: ApplicationFiled: October 20, 2014Publication date: February 5, 2015Inventors: Fernando Jose Rebelo Do Couto, KRISTIN BETH HENDRICKS, STACEY ELLEN WALLACE, GUO-LIANG YU
-
Publication number: 20140309127Abstract: Compositions and methods for detecting bladder cancer are provided. In some embodiments, methods of detecting low grade bladder cancer are provided. In some embodiments, methods of monitoring recurrence of bladder cancer are provided. In some embodiments, the methods comprise detecting androgen receptor (AR) and/or uroplakin 1B (UPK1B).Type: ApplicationFiled: March 6, 2014Publication date: October 16, 2014Applicant: CepheidInventors: Leena McCann, Stacey Ellen Wallace, Edwin Wei-Lung Lai, Russell Higuchi
-
Patent number: 8444984Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: June 7, 2012Date of Patent: May 21, 2013Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Publication number: 20120269809Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: ApplicationFiled: June 7, 2012Publication date: October 25, 2012Inventors: FERNANDO JOSE REBELO DO COUTO, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Patent number: 8211433Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: April 29, 2011Date of Patent: July 3, 2012Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Publication number: 20110243936Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: ApplicationFiled: April 29, 2011Publication date: October 6, 2011Inventors: FERNANDO JOSE REBELO DO COUTO, KRISTIN BETH HENDRICKS, STACEY ELLEN WALLACE
-
Patent number: 7959921Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: August 21, 2008Date of Patent: June 14, 2011Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Publication number: 20090202558Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: ApplicationFiled: August 21, 2008Publication date: August 13, 2009Inventors: FERNANDO JOSE REBELO DO COUTO, Kristin Beth Hendricks, Stacey Ellen Wallace
-
Patent number: 7431927Abstract: The invention provides monoclonal antibodies that neutralize TNF? activity. The monoclonal antibodies may be rabbit monoclonal antibodies or monoclonal antibodies having CDR regions derived from those rabbit monoclonal antibodies. In certain embodiments, the monoclonal antibodies may be humanized. Methods of using the subject antibodies to inhibit TNF? activity, methods of treatment using those antibodies and kits containing the same are also provided. The invention finds use in a variety of research and medical applications.Type: GrantFiled: March 24, 2005Date of Patent: October 7, 2008Assignee: Epitomics, Inc.Inventors: Fernando Jose Rebelo Do Couto, Kristin Beth Hendricks, Stacey Ellen Wallace